Navigation Links
Osteotech Reports Fourth Quarter and Full Year 2009 Financial Results
Date:3/4/2010

s based upon periodic forecast requirements and available tissue supply.
  • Also during the fourth quarter, the Company announced Plexur M had been utilized in a variety of surgeries focused on orthopedic trauma, joint replacements and oncology-related procedures.
  • Late in the fourth quarter, Osteotech submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) to obtain marketing clearance for the use of its Duratech BioRegeneration Matrix to repair or replace the dura mater in various cranial surgical procedures.  The Company expects to receive preliminary feedback from the FDA regarding the pending application late in the first quarter of 2010.
  • Early in the first quarter of 2010, the Company announced that it expanded its financial flexibility with a new, unused $10 million line of credit established in late December.  This new line of credit, coupled with the Company’s cash position and the consideration it will receive from a new licensing agreement, should provide the resources necessary to allow Osteotech to continue to execute its growth strategy.
  • The Company is scheduled to make a corporate presentation to investors at the Canaccord Adams Musculoskeletal Conference on March 9, 2010.
  • Osteotech intends to showcase its new proprietary biologic product portfolio at its booth (Booth No. 1061) during the Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), in New Orleans, Louisiana from March 10 to 12, 2010.  A number of surgeons will present the clinical results stemming from their use of MagniFuse and Plexur M at the Osteotech booth during the meeting.  


  • '/>"/>
    SOURCE Osteotech, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix
    2. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
    3. Osteotechs MagniFuse(TM) Technology Used in First U.S. Surgery
    4. Osteotech Reports Third Quarter 2009 Financial Results
    5. Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting
    6. Osteotech Announces Preliminary Fourth Quarter 2009 Revenue
    7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    8. Spherix Reports Second Quarter Earnings
    9. Tapestry Reports Second Quarter 2007 Results
    10. Callisto Reports on Second-Quarter 2007 Milestones
    11. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health ... several new IT value-added reseller (VAR) national contracts that ... goods and services at lower costs. These include manufacturer ... such as initiative assistance and ongoing IT consulting support. ...
    (Date:1/15/2014)... plc (LSE: SHP, NASDAQ: SHPG ) announces that it ... the announced tender offer for all of the outstanding shares of ... the waiver, the transaction is no longer conditional on OFT approval, ... 2014 following the currently scheduled expiration time, subject to the satisfaction ...
    (Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
    Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
    ... SPRING HARBOR, N.Y., Sept. 1 The ASCO ... Advisory Committee (ODAC) recommendation that the breast cancer indication ... voting members, breast cancer specialists, oncologists in private practice, ... available online now at ASCOPost.com and appear in the ...
    ... According to Millennium Research Group (MRG), the global authority on ... continue to be used in a narrow set of indications ... grow at a much lower rate than previously expected.  With ... compared to the nonfusion market as a whole which is ...
    Cached Medicine Technology:The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer 2The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer 3European Interspinous Process Decompression Device Market Will Grow Nominally at 1.2% over the Next Five Years 2European Interspinous Process Decompression Device Market Will Grow Nominally at 1.2% over the Next Five Years 3
    (Date:4/24/2014)... professor in the new Institute for Biomedical Sciences ... $2.83 million federal grant to develop novel therapeutics ... grant from the Eunice Kennedy Shriver National Institute ... National Institutes of Health will support Plemper,s drug ... at least one distinct alternative compound. , Infections ...
    (Date:4/24/2014)... to give than to receive at least if you,re ... , The study found that 15- and 16-year-olds who find ... family members, are less likely to become depressed than those ... the money for themselves. , The researchers detail their findings ... . , The study focused on the ventral striatum, a ...
    (Date:4/24/2014)... pH1N1 virus caused the first flu pandemic in the ... and killed more than 50 people in the country. ... flu epidemics (winter/spring seasons). , Infections with influenza ... World Health Organization has recommended Tamiflu for treatment of ... this drug is that it targets viral proteins which ...
    (Date:4/23/2014)... Moffitt Cancer Center researchers say clinical trials for ... leukemia (AML) are very promising. Patients treated with ... and daunorubicin, are showing better responses than patients ... , "Acute myeloid leukemia is an aggressive ... success, especially in older patients," explained Jeffrey Lancet, ...
    (Date:4/23/2014)... to high-energy particles, simulating conditions astronauts would face on ... and slower reaction times, even when the radiation exposure ... impairments which affected a large subset, but far ... linked to protein changes in the brain, the scientists ... humans, suggest it may be possible to develop a ...
    Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3
    ... in the cereal category as they provide fibre beta glucan ... health-conscious consumers. So there is news to cheer now as ... called beta-glucan in their diets.,This variety of oats has been ... University (NDSU) scientists., ,Beta-glucan can help lower blood levels ...
    ... A new study has found that at high doses, ... result in liver damage, leading to significant health risks. ... University of Toronto, results of which can be found ... ,Previous studies have demonstrated the anti-oxidant effects of ...
    ... found out that retinal examination of a child, to determine the ... of abuse. // This was discussed in the American Academy of ... is a light sensitive tissue located behind the eye. Any rupture ... the result is bleeding or retinal hemorrhage. , A ...
    ... a molecular computer, which uses enzymes to perform calculations ... release of drugs.// ,Itamar Willner, who built ... Jerusalem in Israel, said the enzyme-powered computers could have ... future, be implanted into humans. ,The researchers ...
    ... California was slapped with four additional law suits, after the ... miserably. // ,Orange county Superior court has ... of patients who died just waiting for the transplants; the ... ,The liver transplant program transparent to gross mismanagement has to ...
    ... of doctors at the U.S. military prison in Guantanamo ... strike) through insertion of feeding tubes // through their ... who claim that such practices violate the fundamental principles ... are being subjected to harsh interrogations, targeted at extension ...
    Cached Medicine News:Health News:Retinal Hemorrhage: No More a Sure Sign of Child Abuse 2Health News:Medical Ethics Violated By Prison Officials In Guantanamo Bay 2
    The INSIGNIA® pacing systems allow the physician to provide customized adaptive-rate pacing therapy to meet individual patient needs....
    ... less than thirty pounds, the EUB 405 ... quality. Compatible with a wide range of ... solution for a variety of clinical settings. ... easy to operate. It includes an alphanumeric ...
    ... The HI VISION 6500 ... offers advanced clinical imaging, enhanced ... flexibility, all in robust and ... a better clinical solution in ...
    ... The PENTAX FG-36UX provides a wide range ... It is also possible to obtain a clear ... Flow Mapping and Color Flow Angio. An accessory ... has improved. Those feature make it possible for ...
    Medicine Products: